Background: The NCI-MATCH trial is the largest national study (1173 sites) for pts with relapsed/ refractory solid tumors, lymphomas and myeloma, which assigns targeted therapies based on individual tumor molecular alterations detected using the adapted Oncomine AmpliSeq panel (143 genes) and immunohistochemistry (IHC). We hypothesized that patients with PTEN-deficient cancers enrolled to Arms N and P may benefit from treatment with the PI3K beta-selective inhibitor GSK2636771. Methods: Eligibility: relapsed/refractory ca, good end-organ function, and ECOG PS 1. Pts were screened for molecular alterations by centralized testing on fresh tumor biopsy and had deleterious PTEN mut/del without loss of expression (Arm N) or complete loss of cytoplasmic and nuclear PTEN staining on IHC (Arm P), and no other aberrations activating the PI3K/MTOR and MAPK pathways (mut in PIK3CA, PIK3R1, BRAF, KRAS, AKT1, TSC1/2, mTOR, RHEB, NF2, NRAS, HRAS). Pts received GSK2636771 400mg/day (28-days cycles). RECIST 1.1 overall response rate (ORR) was the primary endpoint. Results: Of 59 enrolled pts, 56 were eligible and received treatment. Of 22 pts with PTEN mut/del (Arm N: 6 uterine, 2 breast, 2 prostate, 2 head/neck ca, 10 other), all are off treatment as of analysis (14 disease progression, 4 for adverse events [AEs], 4 other). One pt (4.5%) with prostate ca (PTEN deletion, MPRSS2-ERG fusion) attained a partial response (-42%). Of 7 (32%) pts with stable disease (SD), 2 had SD > 6 months (uterine leiomyosarcoma; endometrial carcinoma). Of 34 pts with loss of PTEN protein by IHC (Arm P: 7 prostate, 6 breast, 3 squamous anal ca, 2 cholangiocarcinoma, 16 other), all are off treatment as of analysis (26 disease progression, 4 for AE, 4 other). Of 9 (37.5%) pts with SD, 3 had SD > 6 months (prostate cancer; squamous bladder cancer, squamous anal cancer). Median progression-free survival was 1.8 months for both arms. Gr 3 treatment-related (tr) reversible toxicities were experienced by 30% (7) and 20% (7) of pts in arms N and P, respectively. No tr Gr 5 toxicities were observed in either arm. Conclusions: Single agent GSK2636771 has very modest activity in ca with PTEN gene mutation/deletion and/or PTEN protein loss. Clinical trial identification: NCT02465060. Legal entity responsible for the study: NCI ECOG-ACRIN. Background: In this era of personalized medicine there is outburst of information and plethora of new treatment strategy. Data Tsunami overwhelms human cognitive capacity. Artificial intelligence is being used for information-intensive decision making.
We present here an experience with this technology in cancer treatment decision support. Methods: WFO was used to obtain treatment recommendations of cases that were previously evaluated by a MDT at a major cancer center in India between 2014 and 2016. A comparison was made between the oncology advisor's recommended treatment and that of the tumor board. Treatment concordance was defined as a tumor board recommendation falling into the oncology advisor's categories of "recommended" or "for consideration" treatments. All non-concordant cases (n ¼ 33) were re-presented to the tumor board in a blinded fashion in 2016 to address time of evaluation differences between the tumor board and the oncology advisor. Results are presented as the proportion of concordant cases. Results: From 2014-2016 we had 126 colon cancers & 124 rectal cancers. Of colon 62 & 64 were non-metastatic & metastatic respectively, whereas in rectal cancer it was 93 & 31 respectively. Mean age of the patient was 55 years. The overall concordance at first analysis was 87%. At sub group analysis in colon (85% vs 77%) & rectum (97%vs81%) & Overall (92% vs78%) non-metastatic cases had higher concordance level than metastatic cases (Table1). There were 31 cases which were non-concordant that were rechallenged to MDT. After second review the overall concordance level improved from 87% to 95%. Conclusions: Artificial intelligence treatment recommendations with Watson for Oncology showed high levels of concordance with a multidisciplinary tumor board. This cognitive computing technology holds much promise in helping oncologists make information intensive, evidence based treatment decisions.These findings are encouraging for the use of this technology. Additional investigations are needed to understand concordance in settings where cancer expertise and treatment options may differ. Legal entity responsible for the study: Ethics Board Committee, Manipal Hospitals Bangalore. Background: ODM-203 is an orally available small molecule with balanced inhibitory effects on FGFR 1-4 and VEGFR 1-3 subtypes. We present here results of the phase 1/2 KIDES study. Methods: The KIDES study is an open-label, non-randomized, multicentre phase 1/2 first-in-man study of ODM-203 in patients with advanced solid tumors. In the Part 1 dose escalation (3 þ 3), ODM-203 was evaluated in 31 patients between 50-800mg daily with food to identify the maximum tolerated dose (MTD). Part 2 expansion included 53 patients to evaluate a new formulation, the recommended phase 2 dose and the dose schedule. Patients continued ODM-203 treatment until disease progression or dose limiting toxicity. Results: 84 patients (median 57 years, range 28-80), with the most common tumor types being cholangio, breast, colorectal, endometrium, ovarian and thyroid carcinoma, were included, with most patients in Part 2 having FGFR alterations. Six patients remain on treatment. In the dose-escalation Part 1, 800mg/day was considered the highest dose that could not be tolerated although MTD was not formally identified. This was because of a general adverse event (AE) burden and increased bilirubin in most patients. Bilirubin increase was due to UGT1A1 inhibition by ODM-203 and resolved in all cases upon dose reduction/interruption. In Part 2, the optimal dose was determined to be 400mg/day with food. Most AE's were grade 1-2, the most common ones being increased bilirubin (76%), fatigue and asthenia (68%), diarrhoea (60%), stomatitis (41%), arthralgia (41%) and decreased apetite (41%). Most common grade >3 AE's were bilirubin increase (45%), fatigue (6%) and diarrhoea (6%). There were 6 (9%) partial responses (PR) and additionally 24 (35%) patients achieved target lesion reduction. In total, 30 (44%) patients had disease stabilisation (SD) with median of 21 weeks on the study. The clinical benefit rate (CR þ PR þ SD) was 36/69 (52%). 
